Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC Objectives To assess the effectiveness and safety of pembrolizumab monotherapy and in combination with chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC). Introduction Historically, patients with advanced NSCLC have a poor prognosis despite the use of platinum-based chemotherapy drugs. The 5-year relative survival rate of
Tag: immunotherapy
Renal Cell Carcinoma- Prognosis via Albumin Levels
Renal Cell Carcinoma- Prognosis via Albumin Levels Metastatic renal cell carcinoma (mRCC) - An Introduction Renal cell carcinoma (RCC) constitutes approximately 90% of all urologic malignancies. Approximately 30% of patients with RCC present with metastatic disease, and amongst those with localized disease, a substantial proportion will recur. Before 2005, immunotherapy with interleukin-2
